Lina-DKD 5mg Tablet contains Linagliptin, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. By inhibiting the DPP-4 enzyme, Linagliptin enhances the levels of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner, thereby improving glycemic control. Lina-DKD is typically prescribed as monotherapy or in combination with other antidiabetic agents such as metformin or sulfonylureas when diet and exercise alone do not provide adequate glycemic control. The 5mg dosage is administered orally once daily, with or without food, and does not require dose adjustment in patients with renal impairment, making it a suitable option for diabetic patients with compromised kidney function. Clinical trials have demonstrated that Lina-DKD effectively reduces HbA1c levels with a low risk of hypoglycemia and a favorable safety profile. Common adverse effects may include nasopharyngitis, headache, and upper respiratory tract infections, though serious side effects are rare. As with all antidiabetic therapies, regular monitoring of blood glucose and renal function is recommended to optimize treatment outcomes and ensure patient safety.